Virpax Pharmaceuticals, Inc. (VRPX)
| Market Cap | 1.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.89M |
| Shares Out | 2.74M |
| EPS (ttm) | -14.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 79,056 |
| Open | 0.540 |
| Previous Close | 0.501 |
| Day's Range | 0.495 - 0.540 |
| 52-Week Range | 0.460 - 11.400 |
| Beta | 1.23 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Aug 12, 2024 |
About VRPX
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal s... [Read more]
Financial Performance
Financial StatementsNews
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at 2024 BIO International Convention.
Virpax Announces Pricing of $2.25 Million Public Offering
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Pricing of $2.25M Public Offering.
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments
BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2024 First Quarter Results and Recent Developments.
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Results of MTD Study for Probudur. Liposomal Formulation Developed to Provide Both Immediate and Sustained Pain Relief.
Virpax Pharmaceuticals Reports 2023 Year-End Results
BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2023 Year-End Results.
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price.
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Preliminary Results of Probudur™ Pilot Study with the U.S. Army Institute of Surgical Research.
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Results of Special Shareholders Meeting.
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing.
Virpax Pharmaceuticals Announces Leadership Transition
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Leadership Transition.
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Reports 2023 Third Quarter Results and Recent Developments.
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review.
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Extension of CRADA with the U.S. Army Institute of Surgical Research.
Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Results of Probudur™ Dose Escalation Studies.
Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at the LD Micro Main Event XVI.
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
LAVAL, Québec--(BUSINESS WIRE)-- #Altasciences--Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company specializing in developing non-addictive...
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces the Formation of Novvae™ Pharmaceuticals.
Virpax Pharmaceuticals Updates on Litigation
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-...
Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at H.C. Wainwright 25th Annual Global Investment Conference.
Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments
BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2023 Second Quarter Results and Recent Developments.
Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-...
Virpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Ring NASDAQ Closing Bell on July 24, 2023.
Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments
BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2023 First Quarter Results and Recent Developments.
Nanomerics Announces Ocular Molecular Envelope Technology (MET) Patent Granted in Canada
LONDON, UK / ACCESSWIRE / April 13, 2023 / Nanomerics Ltd., a private speciality pharmaceutical company today announced that the Company had been granted patent protection in Canada for the ocular use...